Experimental combo therapy aims to outsmart lymphoma
NCT ID NCT05801913
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new approach for people with intermediate or high-grade B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It combines specially engineered immune cells (CAR T cells) that target cancer cells with a vaccine designed to boost the immune response. The main goals are to see if the combination is safe and feasible to produce and deliver.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CMV-specific CD19-CAR T cells and CMV-MVA triplex vaccine
- What this could lead to
- If successful, this approach could offer a new treatment option for patients with hard-to-treat B-cell non-Hodgkin lymphoma that has returned or not responded to standard therapy.
- What could go wrong
- This is a very early phase 1 trial with only 15 participants, so it is primarily testing safety and feasibility. The treatment may not work, and there are risks of serious side effects like cytokine release syndrome and neurotoxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE B-CELL NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- Engineered immune cells take on tough blood cancers in early trial
- Brain training before CAR-T may protect memory, study hopes
- Supercharged immune cells take on tough B-Cell cancers in early trial
- New drug cocktail aims to outsmart Hard-to-Treat lymphoma
- Can a pill make CAR T-Cell therapy last longer?